» Articles » PMID: 17316146

Comparison of Oxidative Stress Markers After Intravenous Administration of Iron Dextran, Sodium Ferric Gluconate, and Iron Sucrose in Patients Undergoing Hemodialysis

Overview
Journal Pharmacotherapy
Specialty Pharmacology
Date 2007 Feb 24
PMID 17316146
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Study Objective: To compare non-transferrin-bound iron and markers of oxidative stress after single intravenous doses of iron dextran, sodium ferric gluconate, and iron sucrose.

Design: Prospective, open-label, crossover study.

Setting: University-affiliated general clinical research center.

Patients: Twelve ambulatory patients undergoing hemodialysis.

Intervention: Patients received 100 mg of intravenous iron dextran, sodium ferric gluconate, and iron sucrose in random sequence, with a 2-week washout period between treatments.

Measurements And Main Results: Serum samples for transferrin saturation, non-transferrin-bound iron, and malondialdehyde (MDA; marker of lipid peroxidation) were obtained before (baseline) and 30, 60, 120, and 360 minutes and 2 weeks after each iron infusion. A serum sample for hemeoxygenase-1 (HO-1) RNA was obtained at baseline and 360 minutes after infusion. Non-transferrin-bound iron values were significantly higher 30 minutes after administration of sodium ferric gluconate and iron sucrose compared with iron dextran (mean +/- SEM 10.1 +/- 2.2, 3.8 +/- 0.8, and 0.23 +/-0.1 microM, respectively, p<0.001 for sodium ferric gluconate vs iron dextran, p = 0.002 for iron sucrose vs iron dextran). A significant positive correlation was noted between transferrin saturation and the presence of non-transferrin-bound iron for sodium ferric gluconate and iron sucrose (r2 = 0.37 and 0.45, respectively, p<0.001) but not for iron dextran (r2 = 0.09). After sodium ferric gluconate, significantly more samples showed increases in MDA levels from baseline compared with iron sucrose and iron dextran (p = 0.006); these increased levels were associated with the presence of non-transferrin-bound iron, baseline transferrin saturation above 30%, baseline transferrin levels below 180 mg/dl, and ferritin levels above 500 ng/ml (p<0.05). However, only a transferrin level below 180 mg/dl was independently associated (odds ratio 4.8, 95% confidence interval 1.2-15.3).

Conclusion: Iron sucrose and sodium ferric gluconate were associated with greater non-transferrin-bound iron appearance compared with iron dextran. However, only sodium ferric gluconate showed significant increases in lipid peroxidation. The relationship between non-transferrin-bound iron from intravenous iron and oxidative stress warrants further exploration.

Citing Articles

Plasma non-transferrin-bound iron uptake by the small intestine leads to intestinal injury and intestinal flora dysbiosis in an iron overload mouse model and Caco-2 cells.

Zhang Q, Ding H, Yu X, Wang Q, Li X, Zhang R Sci China Life Sci. 2023; 66(9):2041-2055.

PMID: 37452897 DOI: 10.1007/s11427-022-2347-0.


Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways.

Garbowski M, Bansal S, Porter J, Mori C, Burckhardt S, Hider R Haematologica. 2020; 106(11):2885-2896.

PMID: 33054113 PMC: 8561294. DOI: 10.3324/haematol.2020.250803.


Role of redox iron towards an increase in mortality among patients: a systemic review and meta-analysis.

Sharma S Blood Res. 2019; 54(2):87-101.

PMID: 31309086 PMC: 6614104. DOI: 10.5045/br.2019.54.2.87.


In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations.

Pai A, Pai M, Meyer D, Bales B, Cotero V, Zheng N Regul Toxicol Pharmacol. 2018; 97:17-23.

PMID: 29857115 PMC: 8855972. DOI: 10.1016/j.yrtph.2018.05.014.


Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake.

Wu M, Sun D, Tyner K, Jiang W, Rouse R Nanomaterials (Basel). 2017; 7(12).

PMID: 29244729 PMC: 5746941. DOI: 10.3390/nano7120451.